1 BTC
=
- USD
NeuroBo Pharmaceuticals, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About NeuroBo Pharmaceuticals, Inc. Common Stock
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
Market Statistics
Trading Metrics
How to Buy NRBO
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy NRBO
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articles
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 250 points on Thursday. The Dow traded up 0.66% to 38,403.91 while the NASDAQ rose 1.01% to 15,316.80. The S&P 500 also rose, gaining, 0.87% to 4,887.70. Check This Out: $320M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying  Leading and Lagging Sectors  Consumer staples shares rose by 1.6% on Thursday. In trading on Thursday, energy shares fell by 0.2%.  Top Headline  Honeywell International Inc (NASDAQ: HON) reported downbeat revenue for its fourth quarter and issued weak outlook. Honeywell reported fourth-quarter fiscal 2023 sales of $9.44 billion, up 3% year-over-year on a reported basis and +2% on an organic basis, missing the consensus of $9.70 billion. Adjusted EPS was $2.60 (+3% Y/Y), beating the consensus of $2.59. For the first quarter, Honeywell sees adjusted EPS of $2.12-$2.22 (consensus $2.24) and sales of $8.9 billion-$9.2 billion (consensus $9.248 billion).  Equities Trading UP  Cimpress plc (NASDAQ: CMPR) shares shot up 23% to $92.54 after the company reported better-than-expected second-quarter financial results and said the board authorized the repurchase of up to $150 million of company shares. Shares of NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) got a boost, surging 72% to $5.61 after the company announced FDA clearance of the IND for a Phase 1 clinical trial of DA-1726 ...
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results. C.H. Robinson Worldwide posted adjusted earnings of 50 cents per share, missing market estimates if 81 cents per share. The company’s quarterly sales came in at $4.20 billion versus estimates of $4.34 billion. C.H. Robinson Worldwide shares dipped 12.6% to $73.49 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Minim, Inc. (NASDAQ: MINM) shares climbed 57.3% to $6.45. David E. Lazar recently disclosed a 51% active stake in Minim. Clearmind Medicine Inc. (NASDAQ: CMND) jumped 51% to $2.17. Clearmind Medicine announced long-term licensing agreement with BIRAD. NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) climbed 52.9% to $5.00. NeuroBo Pharmaceuticals announced FDA clearance of IND for Phase 1 clinical trial of DA-1726 for the treatment of obesity. FibroBiologics, Inc. (NASDAQ: FBLG) shares climbed 47.4% to $42.90. FibroBiologics announced direct listing on the NASDAQ. Celularity Inc. (NASDAQ: CELU) rose 36% to $0.5191. Celularity said it sees FY24 net sales of $50 million to $56 million. Cimpress plc (NASDAQ: CMPR) jumped 28.8% to $96.90 after the company reported better-than-expected second-quarter financial results and said the board authorized the repurchase of up to $150 million of company shares. TuSimple Holdings Inc. (NASDAQ: TSP) rose 28% to $0.2950. Elevai Labs, Inc. (NASDAQ: ELAB) gained 23.5% to $0.84 after gaining 8% on Wednesday. Asset Entities Inc. (NASDAQ: ASST) climbed 22.8% to $0.5650. Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares jumped 20.4% to $0.6649. Kiora Pharmaceuticals announced a private placement of up to $45 million. Evaxion Biotech A/S (NASDAQ: EVAX) gained 19.5% to $4.70. Evaxion Biotech announced pricing of $15 million public offering of 3.750 million ADS at $4.00 per ADS. Nextracker Inc. (NASDAQ: NXT) rose climbed 18.8% to $53.79 after the company reported better-than-expected third-quarter financial results. SunPower Corporation (NASDAQ: SPWR) jumped 18.1% to $3.5791. BioRestorative Therapies, Inc. (NASDAQ: BRTX) gained 16.4% to $1.8850. Corteva, Inc. (NYSE:
U.S. stocks traded higher midway through trading, with the S&P 500 gaining around 0.5% on Thursday. The Dow traded up 0.23% to 38,238.99 while the NASDAQ rose 0.54% to 15,245.46. The S&P 500 also rose, gaining, 0.48% to 4,868.71. Check This Out: $320M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying  Leading and Lagging Sectors  Consumer staples shares rose by 1.4% on Thursday. In trading on Thursday, financial shares fell by 0.9%.  Top Headline  The ISM manufacturing PMI rose to 49.1 in January, notching the highest level since Oct. 2022, compared to 47.1 in December, and topping market estimates of 47.  Equities Trading UP  Cimpress plc (NASDAQ: CMPR) shares shot up 24% to $93.21 after the company reported better-than-expected second-quarter financial results and said the board authorized the repurchase of up to $150 million of company shares. Shares of NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) got a boost, surging 55% to $5.07 after the company announced FDA clearance of the IND for a Phase 1 clinical trial of DA-1726 for the treatment of obesity. Celularity Inc. (NASDAQ: CELU) shares were also up, gaining 28% to $0.4861. Celularity said it sees FY24 net sales of $50 million to $56 million.  Equities Trading DOWN  Revelation Biosciences, Inc. (NASDAQ: ...
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.14% to 38,204.88 while the NASDAQ rose 0.77% to 15,281.03. The S&P 500 also rose, gaining, 0.49% to 4,869.54. Check This Out: $320M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying  Leading and Lagging Sectors  Communication services shares rose by 1.5% on Thursday. In trading on Thursday, utilities shares fell by 0.6%.  Top Headline  U.S. initial jobless claims increased to 224,000 in the week ended January 27, versus a revised 215,000 in the prior week and compared to market estimates of 212,000.  Equities Trading UP  Minim, Inc. (NASDAQ: MINM) shares shot up 83% to $7.50. David E. Lazar recently disclosed a 51% active stake in Minim. Shares of NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) got a boost, surging 40% to $4.58. NeuroBo Pharmaceuticals announced FDA clearance of IND for Phase 1 clinical trial of DA-1726 for the treatment of obesity. FibroBiologics, Inc. (NASDAQ: FBLG) shares were also up, gaining 20% to $35.00. FibroBiologics announced direct listing on the ...
